In conclusion, our findings demonstrate for the first time that the second-generation proteasome inhibitor MLN9708 is cytotoxic to various breast cancer cells (ER/PR+/−, HER2+, or triple-negative) and can induce cell death. This evidence concerns the gene ESR1 and breast carcinoma.